- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04423081
Cross-cultural Adaptation and Validation of the French Version of the EXIT (EXperiences of Induction Tool) (EXIT) (EXIT)
Cross-cultural Adaptation and Validation of the French Version of the EXIT (EXperiences of Induction Tool) Self-questionnaire Assessing Women's Feelings About the Onset of Childbirth
Study Overview
Detailed Description
Favourable agreement was obtained from the authors to adapt the Australian moose tool in a cross-cultural manner. None of the co-authors expressed a desire to collaborate on our project. The EXIT questionnaire is free of rights.
The translation of the EXIT questionnaire into French will be carried out according to the recommended steps of the cross-cultural adaptation process (21, 22, 25): translation of the source version into French by three native French translators, adaptation of the different translations by a group of experts, back translation by two native English speakers, testing with a panel of women who have been triggered for childbirth, in order to arrive at the final version which will be evaluated in a sample of the target population.
Information about the study will be given to women between Day 2 and Day 4 postpartum. Patients' non-opposition to participate in this study will be collected in the patient's medical record.
Recruitment of subjects: the study will be proposed to all eligible women who have been induced for their delivery and with an unfavourable cervix in the obstetrics department of the CHU Estaing, Clermont-Ferrand.
Completion of the questionnaire: women will complete the EXIT self-questionnaire between D2 and D4 post-delivery.
The data collection will include additional socio-demographic and clinical information for each woman participating in the study from their medical records.
The test-retest involves filling in the EXIT questionnaire twice at one to two week intervals.
The women will be contacted by phone one week after the first EXIT test, to inform them that a link will be sent by e-mail to complete the EXIT questionnaire online (on Redcap) a second time. They will be called back a second time a week later if the questionnaire is not completed online.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Clermont-Ferrand, France, 63000
- CHU de Clermont-Ferrand
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients having given birth in the obstetrics department of CHU Estaing, Clermont-Ferrand
- with an induction of labor
- with an unfavorable cervix (Bishop score <6)
- on living child(ren)
- Patients aged 18 years and over, understanding, speaking and reading French
- no object to participating in the study.
Exclusion Criteria:
- Patients induced at first with syntocinon.
- Patients who do not have an internet connection and an e-mail address.
- Patients under legal protection (guardianship, tutorship).
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The psychometric properties of the French version of the EXperiences of Induction Tool
Time Frame: Day 2
|
The psychometric properties of the French version of the EXperiences of Induction Tool include: acceptability, internal structure validity, convergent validity, structure validity against external criteria and reproducibility.
EXperiences of Induction Tool is composed of 3 dimensions: "Time taken to give birth", "Discomfort with IOL" and "Experience of subsequent contractions".
Each dimension has a minimum score of 0 and a maximum score of 5.
For the dimension "Time taken to give birth, a high score mean a more positive feeling.
For "Discomfort with IOL"a high score mean more discomfort.
For "Experience of subsequent contractions", a high score mean a more positive feeling.
|
Day 2
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Score of the EXperiences of Induction Tool
Time Frame: Day 2
|
Score of the EXperiences of Induction Tool will be calculated.
EXperiences of Induction Tool is composed of 3 dimensions: "Time taken to give birth", "Discomfort with IOL" and "Experience of subsequent contractions".
Each dimension has a minimum score of 0 and a maximum score of 5.
For the dimension "Time taken to give birth, a high score mean a more positive feeling.
For "Discomfort with IOL"a high score mean more discomfort.
For "Experience of subsequent contractions", a high score mean a more positive feeling.
|
Day 2
|
Time of birth
Time Frame: at birth
|
delay between induction of labor and birth will be calculated
|
at birth
|
time of labor start
Time Frame: at birth
|
delay between induction of labor and labor start will be calculated
|
at birth
|
Methods of induction of labor
Time Frame: at birth
|
the type of strategy used for induction of labor will be recored
|
at birth
|
Maternal complications
Time Frame: up to 1 week
|
maternal complications include intra-uterine infection, endometritis, c-section, instrumental delivery, post-partum hemorhage, episiotomy
|
up to 1 week
|
Neonatal complications
Time Frame: up to 1 week
|
maternal complications include Apgar score < 7 to 5min, pH and lactates on umbilical arterial sampling, 2nd line operation, and rate of transfer to Intensive care unit, maternal-fetal infection
|
up to 1 week
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- RNI 2020 GALLOT
- 2020-A01286-33. (Other Identifier: ANSM)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Induction of Labor
-
Holy Family Hospital, Nazareth, IsraelRecruitingInduction of LaborIsrael
-
Kazakhstan's Medical University "KSPH"Asfendiyarov Kazakh National Medical UniversityActive, not recruitingInduction of LaborKazakhstan
-
Sorlandet Hospital HFOstfold Hospital Trust; Haukeland University Hospital; St. Olavs Hospital; Nordlandssykehuset...Completed
-
South Warwickshire NHS Foundation TrustWalsall Healthcare NHS Trust; Medicem InternationalTerminated
-
Cairo UniversityMohamed El Sharkawy; Yomna Bayoumi; mohamed hisham gouda; Dina latifCompleted
-
Christian Medical College and Hospital, Ludhiana...Completed
-
Christiana Care Health ServicesCompletedInduction of LaborUnited States
-
Assistance Publique - Hôpitaux de ParisAgence Nationale de sécurité du MédicamentCompleted
-
Icahn School of Medicine at Mount SinaiCompleted
-
University of California, San FranciscoCompletedInduction of LaborUnited States
Clinical Trials on EXIT scale
-
Philips HealthcareTerminatedDelirium of Mixed OriginUnited Kingdom
-
University of PittsburghRecruitingMild Traumatic Brain InjuryUnited States
-
M.D. Anderson Cancer CenterWithdrawn
-
University Hospital, GhentCompletedUterine Cervical NeoplasmsBelgium
-
US Department of Veterans AffairsCompletedProblem Behavior | Dementia, Alzheimer TypeUnited States
-
Edith MarkAalborg University HospitalUnknown
-
Hospices Civils de LyonCompletedChild Psychiatry | Adolescent PsychiatryFrance
-
GCS Ramsay Santé pour l'Enseignement et la RechercheCompletedComplex Post-Traumatic Stress DisorderFrance
-
Jonathan PearlmanCompleted
-
Nanjing Medical UniversityCompleted